Abstract: Techniques for creating an interest graph include obtaining content items from multiple content sources and applying tailored (e.g., source-specific) preprocessing to the content items based on their respective content source. Text is extracted and salient keywords and key phrases are identified using unsupervised machine learning models. The keywords and key phrases become nodes in an interest graph, each node comprising an embedding of a keyword or key phrase in a common embedding space, with edges representing semantic similarity based on embeddings or co-engagement patterns. The graph provides an expansive, granular, and dynamic taxonomy easily adaptable to emerging interests. The interest graph overcomes limitations of conventional taxonomies that lack depth, fail to capture niche interests, and cannot adapt to reflect evolving user preferences. The described techniques construct a rich interest graph from diverse content for improved content understanding.

Abstract: Techniques for automated tagging of visual content are described. A pairwise model is used to encode images and videos with a vision encoder, and encode keywords and phrases from an interest graph with a text encoder. Similarity layers compare these cross-modality embeddings by calculating distance in a shared embedding space. Scores indicate the association between visual features and text. A pairwise loss function brings together matched pairs while separating non-matches during training. Scores exceeding a threshold tag content with relevant keywords and phrases. The pairwise architecture relates images and text despite limited associated text. It leverages vision-to-text understanding for accurate tagging without per-class labels. Contrastive similarity techniques associate visual patterns with textual concepts. Automated tagging organizes user-generated content by topics using this scalable cross-modality approach.

Abstract: Disclosed is an acylated insulin, a pharmaceutical formulation thereof, a pharmaceutical composition thereof with a long-acting GLP-1 compound, and a medical use of the acylated insulin, the pharmaceutical formulation and the pharmaceutical composition. Compared with insulin degludec or other insulin derivatives, the acylated insulin has an unexpected, significantly increased drug effect, a longer duration of action, a longer in vivo half-life, an excellent bioavailability, as well as better physical and chemical stabilities.

Abstract: Provided herein are compositions, systems, and methods comprising effector proteins and uses thereof. These effector proteins may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure may leverage the activities of these effector proteins for the modification, detection, and engineering of nucleic acids.

Abstract: Disclosed is an acylated insulin, a pharmaceutical formulation thereof, a pharmaceutical composition thereof with a long-acting GLP-1 compound, and a medical use of the acylated insulin, the pharmaceutical formulation and the pharmaceutical composition. Compared with insulin degludec or other insulin derivatives, the acylated insulin has an unexpected, significantly increased drug effect, a longer duration of action, a longer in vivo half-life, an excellent bioavailability, as well as better physical and chemical stabilities.

Abstract: GLP-1 derivatives are described. Also described are pharmaceutical compositions and uses of the GLP-1 derivatives.

Abstract: A sterilizing and environment-friendly composite plating layer, a preparation method therefor, and a sterilizing and environment-friendly product. The sterilizing and environment-friendly composite plating layer comprises: a semi-bright nickel layer, a high sulfur nickel layer, and an environment-friendly white chromium composite sterilizing layer; the semi-bright nickel layer is disposed on a substrate that has a sterilizing requirement; the high sulfur nickel layer is disposed on a surface of the side of the semi-bright nickel layer away from the substrate; the environment-friendly white chromium composite sterilizing layer is disposed on a surface of the side of the high sulfur nickel layer away from the substrate; the environment-friendly white chromium composite sterilizing layer has a nano-needle structure and is formed by a sterilizing ammonium salt-containing composite raw material; and the concentration of the sterilizing ammonium salt in the composite raw material is 50 g/L to 100 g/L.

Abstract: An antiviral environment-friendly composite plating layer, a preparation method therefor, and an antiviral environment-friendly product. The antiviral environment-friendly composite plating layer includes: a semi-bright nickel layer, a microporous nickel layer and an environment-friendly black chromium composite antiviral layer; the semi-bright nickel layer is provided on a base material having antiviral requirements; the microporous nickel layer is provided on the surface of the side of the semi-bright nickel layer away from the base material; the environment-friendly black chromium composite antiviral layer is provided on the surface of the side of the microporous nickel layer away from the base material; the environment-friendly black chromium composite antiviral layer has a nanoneedle structure and is formed by a composite raw material containing an antiviral ammonium salt, and the concentration of the antiviral ammonium salt in the composite raw material is 50-100 g/L.

Abstract: The present invention relates to a pharmaceutical combination comprising a PCSK9 inhibitor and a GLP-1 receptor agonist; The invention also relates to the use of the pharmaceutical combination in preparing drugs for treating hyperglycemia, diabetes, obesity and/or cholesterol related diseases.

Abstract: Provided is an insulin derivative, a pharmaceutical formulation thereof, a pharmaceutical composition of same with a long-acting GLP-1 compound, and a medical use of the acylated insulin, said pharmaceutical formulation, and said pharmaceutical composition. In comparison with insulin degludec or other insulin derivatives, the insulin derivative has unexpectedly significantly increased efficacy, longer duration of action, longer half-life in vivo, good bioavailability, and better physical and chemical stability.

Abstract: A novel GLP-1 derivative, compared with GLP-1 derivatives such as liraglutide and semaglutide which are on the market, has comparable or better effect, potency or efficacy, longer or comparable duration of action in vivo or half-life in vivo, has better or comparable GLP-1 receptor binding affinity and has better or comparable DPP-IV stability.

Abstract: The present invention relates to a novel insulin derivative, a pharmaceutical formulation thereof, a pharmaceutical composition thereof with a long-acting GLP-1 compound and medical use of the insulin derivative, the pharmaceutical formulation and the pharmaceutical composition. The novel acylated insulin has surprisingly and significantly increased drug effect, longer duration of action, longer in vivo half-life, good bioavailability and more satisfactory physical stability and chemical stability compared with insulin degludec or other insulin derivatives.

Abstract: Disclosed is an acylated insulin, a pharmaceutical formulation thereof, a pharmaceutical composition thereof with a long-acting GLP-1 compound, and a medical use of the acylated insulin, the pharmaceutical formulation and the pharmaceutical composition. Compared with insulin degludec or other insulin derivatives, the acylated insulin has an unexpected, significantly increased drug effect, a longer duration of action, a longer in vivo half-life, an excellent bioavailability, as well as better physical and chemical stabilities.

Abstract: The present invention relates to methods for preparing 5-fluoro-4-(7?-fluoro-2?-methylspiro[cyclopentane-1,3?-indol]-5?-yl)-N-(5-(1-methylpiperidin-4-yl)pyridin-2-yl)pyrimidin-2-amine and a salt and an intermediate thereof The methods provided herein have improved the existing synthesis methods, simplified the preparation process and increased the yield and purity, and can well meet the requirement of large-scale industrial manufacture.

Abstract: An electrochemical, galvanic type, oxygen sensor including scavenging electrodes for continuously reacting any unreacted or partially reacted active gases, such as oxygen, to remove the active gases prior to being dissolved or have been dissolved in the electrolyte resulting in less than accurate output signals. The use of the scavenging electrodes permits the gas sensor to detect active gases in a gas mixture in sub-parts per billion level accurately and without the need for external sparging of the electrolyte with a pure inert gas. The liquid electrolyte may be stored in the a sol-gel medium formed in sensor container and holding the electrolyte in voids or pockets in the medium thereby rendering the oxygen sensor portable with the stored electrolyte and usable within a few minutes of operation.